| |
No. Patients
|
n (%) with stage III-IV
|
P-value
|
n (%) with grade 3
|
P-value
|
|---|
|
Overall
|
55
|
46 (83.6)
| |
41/54 (75.9)
| |
|
aPresence with CD3
| | | | | |
|
T-PD-1 + CD3
|
44
|
35 (79.5)
|
0.18
|
31 (72.1)
|
0.26
|
|
S-PD-1 + CD3
|
43
|
34 (79.1)
|
0.18
|
34 (81.0)
|
0.13
|
|
Combined PD-1 + CD3
|
47
|
38 (80.9)
|
0.33
|
34 (73.9)
|
0.66
|
|
PD-L1 + CD3
|
18
|
13 (72.2)
|
0.13
|
17 (94.4)
|
0.040
|
|
Presence with FoxP3
| | | | | |
|
T-PD-1 + FoxP3
|
41
|
33 (80.5)
|
0.42
|
30 (75.0)
|
0.99
|
|
S-PD-1 + FoxP3
|
41
|
33 (80.5)
|
0.42
|
33 (82.5)
|
0.075
|
|
Combined PD-1 + FoxP3
|
44
|
36 (81.8)
|
0.67
|
33 (76.7)
|
0.99
|
|
PD-L1 + FoxP3
|
18
|
13 (72.2)
|
0.13
|
17 (94.4)
|
0.040
|
- aEvaluation of the association of the presence of PD-1 or PD-L1 together with CD3 and FoxP3 T cells on advanced disease and on high grade tumors. Significant P-values are indicated in italics
